search
Back to results

Knee Arthritis Treatment With Autologous Fragmented Adipose Tissue and PRP - Comparison of Two Treatment Methods

Primary Purpose

Osteo Arthritis Knee, Knee Osteoarthritis, Knee Pain Chronic

Status
Unknown status
Phase
Phase 2
Locations
Poland
Study Type
Interventional
Intervention
autologous adipose tissue transfer
PRP injections
Sponsored by
Rehasport Clinic
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteo Arthritis Knee focused on measuring knee, arthritis, prp, msc, fat transfer, adipose tissue

Eligibility Criteria

45 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • symptomatic knee OA
  • Kellgren- Lawrence grades I - III OA
  • no or minimal positive effects of previous conservative treatment (rehabilitation, hyaluronic acid injections, steroid injections)
  • VAS pain level minimum 4 in one knee, VAS pain < 2 in the contralateral knee

Exclusion Criteria:

  • Use of local corticosteroids up to three months or hyaluronic acid injections up to six months prior to the study
  • Past or present joint infection
  • Previous knee arthroscopy surgery up to one year prior to examination
  • Peripheral inflammatory diseases (rheumatoid arthritis, spondyloarthropathies, etc.)
  • Total arthroplasty and osteotomy
  • Ankylosis of the joint
  • Dermatitis or dermatological disease at the intended injection site
  • Coexistence of degenerative changes in other limb joints (hip, foot)
  • Cancer
  • Oral corticosteroid therapy
  • Use of medicines that affect blood clotting
  • Pregnancy or breast-feeding

Sites / Locations

  • RehasportRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Autologous Fat Tissue Group

PRP Group

Arm Description

Group of patients treated with intra-articular injections of autologous adipose tissue.

Group of patients treated with intra-articular injections of platelet-rich-plasma.

Outcomes

Primary Outcome Measures

Change in The Knee injury and Osteoarthritis Outcome Score (KOOS)
The answers are given (5 Likert boxes) and each question is assigned a score from 0 to 4. A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) is calculated.
Change in the International Knee Documentation Committee 2000 (IKDC 2000) score
The IKDC contains sections on knee symptoms (7 items), function (2 items), and sports activities (2 items). Scores range from 0 points (lowest level of function or highest level of symptoms) to 100 points (highest level of function and lowest level of symptoms).
Change in tthe Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score
Due to no polish version of the WOMAC score, it will be calculated from KOOS score. Higher scores represent worse pain, stiffness, and functional limitations.
Change in the quality of life score (EQ- 5D- 5L)
The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. Scores range from 5 points (highest level of function and lowest level of symptoms) to 25 points (lowest level of function or highest level of symptoms).
Change in functional status according to The Timed Up and Go Test (TUG)
The result of this test is time measured with stopwatch. Time limit for this test is 3 minutes 30 seconds. Less time means better result.
Change in functional status according to The 5 Times Sit to Stand Test (5xSTS)
The result of this test is time measured with stopwatch. The stopwatch is stopped when the subject sits down after the fifth repetition. Less time means better result.
Change in functional status according to The 10m Walk Test (10mWT)
The result of this test is time measured with stopwatch. The patient is not allowed to run but may use the crutches or a walker if needed. Less time means better result.

Secondary Outcome Measures

Strength parameters
Strength parameters of the knee flexors and extensors the Maximal Voluntary Isometric Contraction (MVIC)

Full Information

First Posted
March 20, 2020
Last Updated
March 24, 2020
Sponsor
Rehasport Clinic
search

1. Study Identification

Unique Protocol Identification Number
NCT04321629
Brief Title
Knee Arthritis Treatment With Autologous Fragmented Adipose Tissue and PRP - Comparison of Two Treatment Methods
Official Title
Autologous Adipose Tissue Injection Versus Platelet-rich Plasma (PRP) Injection in the Treatment of Knee Osteoarthritis: a Randomized, Controlled Study - Study Protocol
Study Type
Interventional

2. Study Status

Record Verification Date
March 2020
Overall Recruitment Status
Unknown status
Study Start Date
July 30, 2018 (Actual)
Primary Completion Date
December 31, 2021 (Anticipated)
Study Completion Date
December 31, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Rehasport Clinic

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a prospective, randomized, controlled study. The purpose of this study is to assess functional and clinical changes among patients with symptomatic knee OA treated with intra-articular injections of autologous adipose tissue or PRP and to compare the efficacy of both therapeutic methods. We hypothesize that adipose tissue injections will improve patients' quality of life and functional status and will decrease pain level significantly more than PRP injections. In addition to the functional tests and muscle strength measurement, the patient reported outcome measures (PROMs) of the knee joint function and quality of life will be used to assess each participant. The same inclusion criteria have been established for an Experimental Group (subjects treated with autologous fat tissue) and a Control Group (subjects treated with PRP). Those criteria consist of: symptomatic knee OA, age between 45 and 65 y.o., Kellgren- Lawrence grades I - III OA, no or minimal positive effects of previous conservative treatment (rehabilitation, hyaluronic acid injections, steroid injections). Those patients who meet inclusion criteria will be allocated to Fat Tissue Group or PRP Group randomly. Patients will be assessed five times: before treatment and 1, 3, 6 and 12 months after the treatment. The PROMs consist of the four questionnaires: The Knee injury and Osteoarthritis Outcome Score (KOOS), International Knee Documentation Committee 2000 (IKDC 2000), the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) (21,22), the Health Questionnaire EQ- 5D- 5L. Moreover, three functional tests will be performed to assess patient's functional status: The Timed Up and Go Test (TUG), The 5 Times Sit to Stand Test (5xSTS), The 10m Walk Test (10mWT). To assess strength parameters of the knee flexors and extensors the Maximal Voluntary Isometric Contraction (MVIC) will be measured. Each test will be supervised by the same one physiotherapist to avoid any interexaminer bias and discrepancies during testing.
Detailed Description
This is a prospective, randomized, controlled study. The purpose of this study is to assess functional and clinical changes among patients with symptomatic knee OA treated with intra-articular injections of autologous adipose tissue or PRP and to compare the efficacy of both therapeutic methods. Lipoaspiration procedure Lipoaspiration will take place in the operating room under general anesthesia for patient's and doctor's comfort. The most frequent donor site is abdomen (14,15). The patient will be placed in a supine position. At first, two small incisions at the level of umbilicus will be made by the trained orthopaedic surgeon (TP or PB). Then Klein solution (saline with lidocaine and epinephrine) will be infused to reduce bleeding. Ten minutes is required for infiltration. Next step is a liposuction performed with a thin cannula inserted through incisions. Finally, skin sutures and the pressure dressing will be applied. To minimize risk of bleeding and hematoma, an elastic belt will be recommended, as well as partial weight bearing within first two weeks. Harvested adipose tissue will be prepared in a Lipogems kit (14). The final product will be transferred into 10-ml syringes. About 10 ml of the product will be injected into the affected knee joint. PRP procedure PRP preparation takes place in an outpatient clinic. 10-ml sterile collecting tubes containing citrate will be placed in a centrifuge (Centrifuge MPV- 223e) with a tilting rotor. Rotation will last 7 minutes at 2054 rounds per minute. After centrifugation, PRP will be collected up to 3 ml for separate 10-ml syringe. 3 ml of PRP will be injected into the knee joint. Procedure will be repeated three times in 7 day interval. Injection procedure Joint injection will be performed by TP or PB in the same manner for both groups: patient placed in supine position, affected knee extended, a 21-Gauge needle inserted into the suprapatellar pouch, in case of joint effusion - aspiration of synovial fluid and finally administration of autologous fat tissue or PRP. This study protocol has several strengths and weaknesses. Undoubtedly one of strongest point of this study is wide, multidimensional functional assessment, which will give a large amount of objective data. To our knowledge, this research is the first one which includes the battery of functional tests and MVIC as an outcome measurement tool. This study will use 4 questionnaires, including WOMAC, which is described by physicians as a gold standard for assessing the effectiveness of knee OA treatment (47,48). On the other hand this study has several limitations. Primarily - the lack of blinding and we consider this as a risk of both, subject and investigator bias. Next and equally important limitation is a small size of the study. Furthermore, autologous fat tissue procedure is definitely more invasive and more stressful for the patients than PRP procedure. Hence, taking all into consideration, to adopt autologous fat tissue as a knee OA therapy, based on the future results, we have to detect definite, statistically significant and clinically noticeable difference. Our PRP procedure gives us the possibility to examine the patient and assess the reaction to intra- articular injection 3 times (3 injections) in 7 day interval. These visits are often associated with physical therapy, which consists of manual therapy and individualized exercise program. Autologous fat tissue procedure does not give us such a possibility. The doctor and physiotherapist see the patient on the day of the surgery and two weeks after, during a control visit, which is also associated with physical therapy. Thus, there are some discrepancies between the two procedures at the beginning of the treatment process. It has been proven that intra- articular injection of autologous fat tissue or PRP is a safety treatment option of knee OA (49,50). The most common complications after the intra- articular injection are pain and swelling of treated knee, but this improve after cold compression and NSAIDs. Also there were no cancer incidents reported after autologous fat tissue or PRP implantation(50). Subject recruitment has started after we received Bioethical Committee approval.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteo Arthritis Knee, Knee Osteoarthritis, Knee Pain Chronic, Knee Arthritis, Knee Disease, Knee Pain Swelling, Joint Diseases
Keywords
knee, arthritis, prp, msc, fat transfer, adipose tissue

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Autologous Fat Tissue Group
Arm Type
Experimental
Arm Description
Group of patients treated with intra-articular injections of autologous adipose tissue.
Arm Title
PRP Group
Arm Type
Active Comparator
Arm Description
Group of patients treated with intra-articular injections of platelet-rich-plasma.
Intervention Type
Combination Product
Intervention Name(s)
autologous adipose tissue transfer
Intervention Description
experimental group: liposuction, adipose tissue preparation and intra-articular injection
Intervention Type
Combination Product
Intervention Name(s)
PRP injections
Intervention Description
control group: blood collection, blood preparation and intra-articular PRP injection
Primary Outcome Measure Information:
Title
Change in The Knee injury and Osteoarthritis Outcome Score (KOOS)
Description
The answers are given (5 Likert boxes) and each question is assigned a score from 0 to 4. A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) is calculated.
Time Frame
1, 3, 6 and 12 months after the treatment
Title
Change in the International Knee Documentation Committee 2000 (IKDC 2000) score
Description
The IKDC contains sections on knee symptoms (7 items), function (2 items), and sports activities (2 items). Scores range from 0 points (lowest level of function or highest level of symptoms) to 100 points (highest level of function and lowest level of symptoms).
Time Frame
1, 3, 6 and 12 months after the treatment
Title
Change in tthe Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score
Description
Due to no polish version of the WOMAC score, it will be calculated from KOOS score. Higher scores represent worse pain, stiffness, and functional limitations.
Time Frame
1, 3, 6 and 12 months after the treatment
Title
Change in the quality of life score (EQ- 5D- 5L)
Description
The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. Scores range from 5 points (highest level of function and lowest level of symptoms) to 25 points (lowest level of function or highest level of symptoms).
Time Frame
1, 3, 6 and 12 months after the treatment
Title
Change in functional status according to The Timed Up and Go Test (TUG)
Description
The result of this test is time measured with stopwatch. Time limit for this test is 3 minutes 30 seconds. Less time means better result.
Time Frame
1, 3, 6 and 12 months after the treatment
Title
Change in functional status according to The 5 Times Sit to Stand Test (5xSTS)
Description
The result of this test is time measured with stopwatch. The stopwatch is stopped when the subject sits down after the fifth repetition. Less time means better result.
Time Frame
1, 3, 6 and 12 months after the treatment
Title
Change in functional status according to The 10m Walk Test (10mWT)
Description
The result of this test is time measured with stopwatch. The patient is not allowed to run but may use the crutches or a walker if needed. Less time means better result.
Time Frame
1, 3, 6 and 12 months after the treatment
Secondary Outcome Measure Information:
Title
Strength parameters
Description
Strength parameters of the knee flexors and extensors the Maximal Voluntary Isometric Contraction (MVIC)
Time Frame
1, 3, 6 and 12 months after the treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
45 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: symptomatic knee OA Kellgren- Lawrence grades I - III OA no or minimal positive effects of previous conservative treatment (rehabilitation, hyaluronic acid injections, steroid injections) VAS pain level minimum 4 in one knee, VAS pain < 2 in the contralateral knee Exclusion Criteria: Use of local corticosteroids up to three months or hyaluronic acid injections up to six months prior to the study Past or present joint infection Previous knee arthroscopy surgery up to one year prior to examination Peripheral inflammatory diseases (rheumatoid arthritis, spondyloarthropathies, etc.) Total arthroplasty and osteotomy Ankylosis of the joint Dermatitis or dermatological disease at the intended injection site Coexistence of degenerative changes in other limb joints (hip, foot) Cancer Oral corticosteroid therapy Use of medicines that affect blood clotting Pregnancy or breast-feeding
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Pawel Bakowski, MD PhD
Phone
0048504759624
Email
pawel.bakowski@o2.pl
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pawel Bakowski, MD PhD
Organizational Affiliation
Rehasport Clinic
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Tomasz Piontek, MD PhD
Organizational Affiliation
Rehasport Clinic
Official's Role
Study Chair
Facility Information:
Facility Name
Rehasport
City
Poznan
State/Province
Wielkopolska
ZIP/Postal Code
60201
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Katarzyna Banaszek, Mrs
Phone
0048616281181
Ext
152
Email
katarzyna.banaszek@rehasport.pl
First Name & Middle Initial & Last Name & Degree
Paweł Bąkowski, MD

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
32434498
Citation
Bakowski P, Kaszynski J, Walecka J, Ciemniewska-Gorzela K, Bakowska-Zywicka K, Piontek T. Autologous adipose tissue injection versus platelet-rich plasma (PRP) injection in the treatment of knee osteoarthritis: a randomized, controlled study - study protocol. BMC Musculoskelet Disord. 2020 May 20;21(1):314. doi: 10.1186/s12891-020-03345-8.
Results Reference
derived

Learn more about this trial

Knee Arthritis Treatment With Autologous Fragmented Adipose Tissue and PRP - Comparison of Two Treatment Methods

We'll reach out to this number within 24 hrs